Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia.

The detection of abnormalities at the retinoblastoma (RB) locus by cytogenetics, Southern blot, and fluorescence in situ hybridization studies suggests that the RB gene has a role in chronic lymphocytic leukemia (CLL). To further study this role, we determined the level of RB protein present in the mononuclear cell fraction derived from peripheral blood or bone marrow samples from 74 patients with CLL, by Western blotting. Compared to similarly prepared samples from the peripheral blood of normal individuals, the level of RB in CLL cells was less than normal in 42% of patients, equal to normal in 22% of patients, and in excess of normal in 36% of patients. Regardless of whether the source of the sample was blood or marrow or if the patients were untreated or previously treated, similar rates of low, normal, and elevated RB levels were observed. RB protein in the CLL patient samples was never phosphorylated. RB levels showed no correlation with the lymphocyte doubling time or with proliferating cell nuclear antigen levels. Low RB levels could arise from genetic alterations of the RB gene or altered regulation of expression. To determine which was occurring, we stimulated the cells from 27 CLL patients in culture with either phytohemagglutinin or pokeweed mitogen in an attempt to induce RB expression and phosphorylation. Among patients with low levels of RB, expression was induced in 46% (6 of 13), and phosphorylation of RB was seen in 31% (4 of 13). Increased expression of phosphorylated RB was induced in 80% (4 of 5) of patients with normal levels of RB and in 78% (7 of 9) of patients with high levels of RB. This study demonstrates that absent RB expression occurs commonly in patients with CLL. Intrinsic abnormalities of the RB gene may be present in those patients with low levels of RB that could not be stimulated by mitogens, while regulatory abnormalities located in trans to the RB gene may occur in the other half. Given the importance that RB levels play in other cancers, the prognostic implication of low RB levels should be studied in CLL.

[1]  R. Weinberg,et al.  Physical interaction of the retinoblastoma protein with human D cyclins , 1993, Cell.

[2]  David M. Livingston,et al.  Functional interactions of the retinoblastoma protein with mammalian D-type cyclins , 1993, Cell.

[3]  A. Sahin,et al.  Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. , 1992, Journal of the National Cancer Institute.

[4]  D. Johnston,et al.  Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. , 1992, Blood.

[5]  G. Gahrton,et al.  Retinoblastoma gene deletions in b‐cell chronic lymphocytic leukemia , 1992, Genes, chromosomes & cancer.

[6]  M. Bar‐eli,et al.  Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia , 1991 .

[7]  H. Saito,et al.  Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. , 1991, Blood.

[8]  Y. Qian,et al.  The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle , 1991, Cell.

[9]  M. Belvin,et al.  Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. , 1991, Oncogene.

[10]  Joseph R. Nevins,et al.  The E2F transcription factor is a cellular target for the RB protein , 1991, Cell.

[11]  M. Raffeld,et al.  Oncogene rearrangements in chronic B-cell leukemia. , 1991, Blood.

[12]  M. Raffeld,et al.  Inactivation of the retinoblastoma gene in human lymphoid neoplasms. , 1991, Blood.

[13]  S. Orrenius,et al.  Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. , 1991, Journal of immunology.

[14]  C. Cordon-Cardo,et al.  Altered expression of the retinoblastoma gene product in human sarcomas. , 1990, The New England journal of medicine.

[15]  M. Cole,et al.  Increased retinoblastoma gene expression is associated with late stages of differentiation in many different cell types. , 1990, Oncogene.

[16]  W. Lee,et al.  Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Knuutila,et al.  Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.

[18]  G. Stein,et al.  Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. , 1990, Science.

[19]  R. Weinberg,et al.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  David M. Livingston,et al.  The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element , 1989, Cell.

[21]  Phang-lang Chen,et al.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation , 1989, Cell.

[22]  J. Varley,et al.  Structural rearrangement of the retinoblastoma gene in human breast carcinoma. , 1988, Science.

[23]  J. Minna,et al.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.

[24]  S. Perry,et al.  Studies of leukocyte kinetics in chronic lymphocytic leukemia. , 1968, Blood.

[25]  P. Nowell,et al.  Cytogenetic Findings and Survival in B-cell Chronic Lymphocytic Leukemia. Second IWCCLL Compilation of Data on 662 Patients. , 1991, Leukemia & lymphoma.

[26]  M. Bar‐eli,et al.  Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. , 1991, Blood.

[27]  M. Seabright,et al.  Chromosome abnormalities involving band 13q14 in hematologic malignancies. , 1987, Cancer genetics and cytogenetics.